Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 0.79 |
| ▸ | GLA | P06280 | 1/20 | 0.79 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.67 |
| ▸ | PDE4A | P27815 | 3/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | MC3R | P41968 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44805 | 0.88 | ADORA2B (1.00) | ADORA2BBLMGLAADORA2APDE4A | |
| SCHEMBL16093733 | 0.82 | ADORA2A (0.70) | ADORA2BBLMGLAADORA2APDE4A | |
| SCHEMBL16697212 | 0.81 | ADORA2A (0.79) | ADORA2BBLMGLAADORA2APDE4A | |
| SCHEMBL4145707 | 0.80 | ADORA2A (0.77) | ADORA2BBLMGLAADORA2APDE4A | |
| SCHEMBL21381247 | 0.80 | PDE4A (1.00) | ADORA2BBLMADORA2APDE4APDE4B | |
| SCHEMBL5463424 | 0.80 | ADORA2A (0.72) | ADORA2BBLMGLAADORA2APDE4A | |
| SCHEMBL8861588 | 0.79 | PDE4A (0.75) | ADORA2BBLMADORA2APDE4APDE4B | |
| SCHEMBL16192700 | 0.79 | ADORA2B (0.68) | ADORA2BBLMGLAADORA2APDE4A | |
| SCHEMBL22342560 | 0.78 | ADORA2B (0.77) | ADORA2BBLMGLAADORA2APDE4A | |
| SCHEMBL23974594 | 0.78 | ADORA2A (0.68) | ADORA2BBLMGLAADORA2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193201-B2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS, LLC (US) | 2012-06-05 | — | — | US | claimed |
| US-20110172253-A1 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2011-07-14 | — | — | US | claimed |
| EP-2338481-A2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | Metaproteomics, LLC (US) | 2011-06-29 | — | — | EP | claimed |
| US-7914831-B2 | Alpha acids, isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids from hops; nontoxic | METAPROTEOMICS, LLC (US) | 2011-03-29 | — | — | US | claimed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | claimed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | claimed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | claimed |
| US-20160128943-A1 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS | KVK-Tech, Inc. (US) | 2016-05-12 | — | — | US | disclosed |
| EP-1718312-B1 | Pharmaceutical compositions comprising hops extract derivatives and caffeine | METAPROTEOMICS LLC (US) | 2015-03-25 | — | — | EP | disclosed |
| WO-2014197601-A1 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS | KVK-Tech, Inc. (US) | 2014-12-11 | — | — | WO | disclosed |
| EP-1915156-B1 | USE OF PSYCHOMOTOR STIMULANTS AND COMPOSITIONS CONTAINING THEM IN A METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTERINE EXHAUSTION | PROVIMI HOLDING B V (NL) | 2012-07-11 | — | — | EP | disclosed |
| US-8193201-B2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS, LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-8092846-B2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | disclosed |
| CN-1946409-A | Synergistic anti-inflammatory pharmaceutical compositions and related methods of using curcuminoids or methylxanthines | METAPROTEOMICS LLC (US) | 2007-04-11 | — | — | CN | disclosed |
| WO-2007021189-A2 | METHOD OF TREATING PARTURIENT PLACENTAL MAMMALS IN ORDER TO REDUCE MATERNAL AND/OR UTIRINE EXHAUSTION | PROVIMI HOLDING B.V. (NL) | 2007-02-22 | — | — | WO | disclosed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | ADORA2B 1339/4885BLM 3909/4885GLA 3687/4885 |
| US-20160128943-A1 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS | SLC18A1, RYR1, SLC6A2 | ADORA2B 130/4885BLM 926/4885GLA 2904/4885 |
| US-20110172253-A1 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | HMOX1, HMOX2, HPGDS | ADORA2B 1339/4885BLM 3909/4885GLA 3687/4885 |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | ADORA2B 1339/4885BLM 3909/4885GLA 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.